95407-10-6

Upstream product

• 95407-07-1 Toluene-4-sulfonic acid (S)-2-benzyloxycarbonylamino-3-methoxymethoxy-propyl ester 
• 501-53-1 benzyl chloroformate 
• 95407-05-9 N-(benzyloxycarbonyl)-O-(methoxymethyl)-L-serine methyl ester 
• 95407-06-0 N-(benzyloxycarbonyl)-O-(methoxymethyl)-L-serinol 
• 1676-81-9 N-benzyloxycarbonyl-L-serine methyl ester 
• 1145-80-8 N-(benzyloxycarbonyl)-L-serine 
• 95406-98-7 N-(benzyloxycarbonyl)-S-methyl-D-cysteine 
• 95407-00-4 N-(benzyloxycarbonyl)-S-methyl-D-cysteine methyl ester 
• 95407-01-5 N-(benzyloxycarbonyl)-S-methyl-D-cysteinol 
• 95407-08-2 N-(benzyloxycarbonyl)-O-(methoxymethyl)-S-methyl-D-cysteinol 

Relevant academic research and scientific papers

Synthesis and activity of pyrimidinylpropenamide antibiotics: The alkyl analogues of sparsomycin

Facile syntheses of sparsomycin (3) and its four analogues (4-7) based on diastereoselective oxidation of sulfide, sulfenylation, and coupling of 6-methyluracylacryllic acid with monooxodithioacetal amine, are described. Studies on the biological activity of morphological reversion on src ts-NRK cells were also carried out.

Synthesis and morphological reversion activity on src(ts)NRK cells of pyrimidinylpropanamide antibiotics, sparsomycin, sparoxomycin A1, A2, and their analogues

Three pyrimidinylpropanamide antibiotics sparsomycin (1), sparoxomycins A1, A2 (2, 3), and also six analogues (4-9) have been synthesized by employing asymmetric sulfide oxidation conditions as a key step. Sparsomycin (1) and its alkyl analogues (5-7) showed higher morphological reversion activities on src(ts)NRK cells than 2 and 3.